natgillin/translations-raw huggingface dataset:
A reactor according to claim 8, characterized in that the driving means are subdivided into two groups (350, 400), each group being connected by said rods to both functional units and in that at least one hardware and/or software device links the said groups with one another so as to ensure that the oscillations of the functional units take place substantially along the direction of a vertical axis not only in counterphase but also synchronously. 
Reaktor u skladu s patentnim zahtjevom &, naznačen time što je pogon podijeljen u dvije skupine (350, 400), gdje je svaka skupina povezana navedenim štapovima s obje funkcionalne jedinice, te što najmanje jedan hardverski i/ili softverski uređaj međusobno povezuje navedene skupine, kako bi se osiguralo da funkcionalne jedinice osciliraju uglavnom u smjeru okomite osi ne samo u protufazi već 1 sinkrono.
While applying the curing light and ultrasonic scaler with a frequency of 42 kHz is used continuously on the treated tooth. 
Tijekom primjene svjetla za očvršćivanje djeluje se kontinuirano s ultrazvučnom sondom frekvnecije od 42 kHz na tretirani zub.
continuously feeding a solution of a cyclic tertiary amine in a suitable solvent or mixture of solvents and an alkylating agent, dissolved in a suitable solvent or mixture of solvents which are aprotic solvents selected among amides, nitriles and sulphoxides, into a continuous-flow reactor; 
kontinuirano napajanje otopine cikličkog tercijarnog amina u pogodnoj otopini ili smjesi otopine i sredstva za alkilaciju, otopljenog u pogodnoj otopini ili smjesi otopine koje su aprotonske otopine odabrane od amida, nitrila i sulfoksida, u reaktor s kontinuiranim protokom;
In another embodiment, in formula (VI), R43 and R44 are, independently, selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu su R43 1 Ru nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil.
The powder is dried in an oven at 60° C. 
Prašak je sušen u peći pri 60 "C.
• substitution of R and/or K by A or a positively charged amino acid; 
• supstitucija R i/ili K s A ili pozitivno nabijene aminokiseline;
The process of claim 1, wherein the ferric chloride is present in the reaction mixture in an amount in the range of from about 30 to about 1000 ppm. 
Postupak prema zahtjevu 1, gdje je željezov(III) klorid prisutan u reakcijskoj smjesi u količini u rasponu od 10 do 1000 ppm.
Glatiramer acetate for use of any one of claims 1-5 to reduce the frequency of relapses in the human patient. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema patentnom zahtjevu 1, naznačen time, da smanjuje atrofiju mozga.
a further functional module is an injector, adapted to be connected, in a transfer phase following the mixing phase as well as in an injection phase following said transfer phase, to the distal end of the main module instead of the closing cap, and to enable the user to inject the bone cement; 
– dodatni funkcionalni modul je jedinica za injiciranje (24), podešena za spajanje, u fazi prijenosa nakon faze miješanja kao i u fazi injiciranja nakon navedene faze prijenosa, s udaljenim krajem (1b) glavnog modula umjesto zatvarača, i za omogućavanje korisniku injiciranje koštanog cementa;
The recombinant adenovirus according to any one of claims 1-6, wherein the recombinant adenovirus further comprises a modified E1a regulatory sequence, wherein at least one Pea3 binding site, or functional portion thereof, is deleted, wherein the functional portion of the at least one Pea3 binding site is a portion of the binding site that, when deleted decreases the binding affinity of the binding site to Pea3. 
Rekombinantni adenovirus u skladu s bilo kojim patentnim zahtjevom 1-5, pri čemu rekombinantni adenovirus nadalje sadrži modificiranu regulatornu sekvencu E1a, pri čemu je najmanje jedno mjesto vezivanja Pea3 ili njegov funkcionalni dio, izbrisan, pri čemu je funkcionalni dio najmanje jednog mjesta vezivanja Pea3 je dio mjesta vezivanja koji, kada je izbrisan smanjuje afinitet vezanja mjesta vezivanja Pea3.
Somatosensory Neglect of the Forepaws . 
in=0) prije početka infuzije
A compound of Formula (I-K): wherein: 
Spoj s Formulom (I-K): [image] naznačen time da:
is a phenyl, 5-membered heteroaryl or 6-membered heteroaryl, wherein any phenyl, 5-membered heteroaryl or 6-membered heteroaryl of R1 is optionally substituted with one or more groups independently selected from halogen, -CN, (C1-C6)alkyl and (C1-C6)haloalkyl; 
je fenil, 5-člani heteroaril ili 6-člani heteroaril, pri čemu je bilo koji fenil, 5-člani heteroaril ili 6-člani heteroaril iz skupine R1 opcionalno supstituiran s jednom ili više skupina zasebno odabranih od halogena, −CN, (C1−C6)alkila i (C1−C6)haloalkila;
The reaction was quenched with 4 mL water and 3 mL 2N NaOH. 
Potom se reakcija prelije s 4 mL; vode 13 mL 2N NaOH.
As stated earlier, these outputs are connected in parallel with the outputs of the conventional controls. 
Kao što je prije bilo navedeno, ovi izlazi su spojeni paralelno s izlazima konvencionalnih kontrola.
wherein the substance binds to activated HGF B chain and inhibits specific binding of said activated HGF B chain to c-met, and wherein the pathological condition is a cancer, tumor, cell proliferative disorder, immune disorder or angiogenesis-related disorder. 
njihova kombinacija, pri čemu se tvar veže na aktivirani HGF B lanac i inhibira specifično vezanje spomenutog aktiviranog HGF B lanca na c-met, i pri čemu patološko stanje je rak, tumor, poremećaj proliferacije stanica, imunosni poremećaj ili poremećaj povezan s angiogenezom.
The solids were purified by preparative HPLC (YMC Combiprep ODS-A, 30 mm×50 mm, MeOH/H2O/0.1% TFA), to give the Intermediate 61 as a white solid (0.024 g, 10% yield). 
Čvrste supstance su pročišćene pomoću preparativne HPLC (YMC Combiprep ODS-A, 30mm x 50mm, MeOH/M20/0.1% TFA), da bi se dobio Intermedijer 61 kao bijela čvrsta supstanca (0.024 g, 10% prinos).
The composition of claim 1, wherein at least one of the one or more isolated monomeric platinum complexes is Trans-1,2-cyclohexanediamine)-trans-dihyroxo(dihydrogen pyrophosphato)platinum(IV). 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platine je (Zrans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
and 4-hydroxybenzoic acid is in the range of about 5:1 to about 1:5. 
Bac i 4-hidroksibenzojeve kiseline iznosi otprilike 1:1, to gdje sukristal ima signal u svom DSC tcrmogramu na otprilike 10
Equisetum extract was dissolved in propylene glycol, then an aqueous solution containing hydroxypropyl chitosan, trimethylacetyl ammonium p-toluenesulfonate and coconut fatty acids diethanolamide were added. 
Ekstrakt Equisetum arvense otopljen je u propilen glikolu, te je potom dodana vodena otopina koja je sadržavala hidroksipropil hitosan, trimetilacetil amonijev p-toluensulfonat i dietanolamid masnih kiselina kokosa.
is phenyl, pyridyl or (1-6C alkyl)OH, wherein said phenyl and pyridyl are optionally substituted with one or more (1-6C)alkyl groups. 
je fenil, piridil ili (1-6C alkil)OH, gdje su navedeni fenil i piridil izborno supstituirani s jednom ili više (1-6C)alkilnih skupina.
with a fermentative organism and/or an enzymatic composition capable of acting on lignocellulosic biomass and comprising at least one isolated or purified polypeptide has an improved endoglucanase activity compared with the endoglucanase activity of the EG2 reference protein, said polypeptide being chosen from the group consisting of: 
- > dodavanja jedne ili više stanica domaćina u skladu s bilo kojim od patentnih zahtjeva 5 do 7, s fermentacijskim organizmom i/ili enzimskim pripravkom u skladu s patentnim zahtjevom 10 na takav način da se dobije fermentirajući mošt;
The programmable electrical control device according to claim 1, wherein the external programming device is any one of a personal computer, comprising a laptop computer, a desktop computer; a smart phone; and a remote control. 
Programabilni električni upravljački uređaj (10) sukladno bilo kojem zahtjeva 1 do 11, naznačen time, što je vanjski uređaj (24b, 24c) za programiranje bilo koji od osobnih računala, uključujući prijenosno računalo, stolno računalo, i slično; pametni telefon; daljinski upravljač; 1 slično.
In another embodiment, the present invention provides compounds of Formula (I) wherein A is selected from the group consisting of n is 0; R1, R2, and R3 are hydrogen; R6 is selected from the group consisting of hydrogen, alkyl, (NRCRD)sulfonyl, and arylalkyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
R4 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila, Spoj za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da je spoj Formule (I) 2-(2-metilpirolidin-2-il)-1H-benzoimidazol-4-karboksamid;
Use of a polypeptide according to claim 1 and/or a composition according to any of claims 10 to 12 to produce sugar from a lignocellulosic material. 
Uporaba polipeptida prema zahtjevu 1 i/ili pripravka prema zahtjevu 9 naznačena time da je za dobivanje šećera iz lignoceluloznog materijala.
In some embodiments, the pharmaceutical composition can comprise rifabutin, amoxicillin and omeprazole. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se sastoji od rifabutina, amoksicilina i omeprazola.
The solid form of the compound of claim 8 having a DSC thermogram substantially as shown in Figure 2. 
Čvrsti oblik spoja prema patentnom zahtjevu 15 koji ima DSC termogram kao što je prikazano na Slici 2, +/- 3°C.
A compound represented by the formula wherein 
Spoj prikazan formulom [image]
The portable cooking and delivery system may further include a securement structure in the cargo compartment of the vehicle that releasably secures the packaging rack in the cargo compartment. 
Prenosivi sustav za kuhanje i dostavu prema zahtjevu 6, naznačen time, da nadalje obuhvaća sljedeće: pričvrsnu konstrukciju u teretnom odjeljku vozila (240), koja odvojivo pričvršćuje rešetkasto postolje za pakiranje (243) u teretnom odjeljku (241).
The anti-IL-5 antibody for the use according to claim 5, wherein the mean plasma concentration of said antibody is 34.1 ± 12.1 µg/mL to 38.2 ± 9.1 µg/mL or wherein the AUC(0-inf) of said antibody is 1110 ± 372 µg×day/mL to 1196 ± 254 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 5, naznačeno time što je srednja koncentracija u plazmi navedenog protutijela 34,1 ± 12,1 µg/ml do 38,2 ± 9,1 µg/ml i/ili što je AUC(0-∞) za navedeno protutijelo 1110 ± 372 µg×dan/ml do 1196 ± 254 µg×dan/ml.
The pharmaceutical composition as claimed in any of Claims 1 to 5, wherein the HMG-CoA reductase inhibitor is selected from a group consisting of Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, and combinations thereof. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je inhibitor reduktaze HMG-CoA odabran iz skupine koju čine: Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin i njihove kombinacije.
A cosmetic composition comprising an effective amount of the compound as defined in claim 1, wherein the effective amount of the compound inhibits proliferation of the pathogenic microorganisms involved in the development of an acne-type skin disorder. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, namijenjen upotrebi u kozmetičkom pripravku, naznačen time što inhibira razmnožavanje patogenih mikroorganizama koji sudjeluju u pojavi poremećaja poput akni na koži, osobito P. acnes.
The pharmaceutical composition for use in the treatment of a non-human mammal which is infested with an ectoparasite according to claim 8, wherein the solid article comprises a polymeric material. 
Farmaceutski pripravak za primjenu za topikalno liječenje ne-humanog sisavca infestiranog s ektoparazitom prema patentnom zahtjevu 7, naznačen time što čvrsti proizvod sadrži polimerni materijal.
is additionally hydrogen, ethoxycarbonyl, ethyl, methoxycarbonyl or methyl, or R5 and R6 together with the carbon they are bonded to form 1-chloro-1-methoxycarbonyl-cyclopropyl, cyclopropyl, 1,1-dichlorocyclopropyl, nitro-cyclopropyl, phenylcarbonyl-cyclopropyl, propen-2-yl-cyclopropyl, or vinyl-cyclopropyl, or 
je dodatno vodik, etoksikarbonil, etil, metoksikarbonil ili metil, ili i R6 zajedno s atomom ugljika na koji su povezani tvore 1-klor-1-metoksikarbonil-ciklopropil, ciklopropil, 1,1-diklorciklopropil, nitro-ciklopropil, fenilkarbonil-ciklopropil, propen-2-il-ciklopropil, ili vinil-ciklopropil, ili
The pharmaceutical composition of claims 9 or 10, wherein the pharmaceutical composition comprises 0.15 mg to 4 mg of the compound, or a pharmaceutically acceptable salt thereof. 
18. Farmaceutski sastav sadrži tvar, ili njenu farmaceutski prihvatljivu sol, iz bilo kojeg od patentnih zahtjeva 1-17 1 farmaceutski prihvatljivi nosač.
The method of claim 1, wherein the compound is 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt thereof. 
Spoj formule I, naznačen time, da je to spoj 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-i1]-N-ciklopropil-4-metil-benzamid, ili njegov farmaceutski prihvatljiv derivat određen u zahtjevu 1, te da je za uporabu prema zahtjevu 1.
said Ang2-binding immunoglobulin single variable domain has the following CDR sequences: 
navedena jednostruka varijabilna domena imunoglobulina koja se veže na Ang2, ima sljedeće CDR-sekvence:
The method according to claim 1, wherein said selection of one of said at least two initial paths according to a cost function comprises calculating at least one of the following cost functions: 
Postupak prema zahtjevu 7, naznačen time da navedeni odabir (2006, 2008) jedne od navedene barem dvije početne putanje (302) prema funkciji troškova sadrži izračunavanje barem jedne od slijedećih funkcija troškova:
A process according to claim 7 and 8 wherein the polymeric matrix consists of polyvinylpyridine or polystyrene. 
Postupak prema patentnim zahtjevima 6 i 7, naznačen time da se polimerna matrica sastoji od polivinilpiriđina ili polistirena.
A method as claimed in claim 1, characterised in that the stretching stage precedes the drawing stage. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, što faza rastezanja prethodi fazi izvlačenja.
Compounds XIII can be prepared using the same techniques as discussed for compounds XII. 
Spojevi XIII mogu se pripraviti jednakom tehnikom kao što je opisano za spojeve XII.
restoring normal glucose tolerance in a diabetic subject, comprising administering to said subject a therapeutically effective amount of said formulation; 
sprječavanje ili liječenje dobivanja na težini, dislipidemije, dijabetesa ili smanjene tolerancije glukoza kod subjekta liječenog antipsihotikom, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije;
an effective amount of a compound having the formula: 
djelotvornu količinu spoja s formulom:
In its centre a similar motif of a smaller diameter was deeper engraved (see FIG. 
U njegovom središtu ugravira so sličan motiv manjeg promjera (vidi Sliku 5a).
An antibody that binds the extracellular domain of PRLR with an equilibrium dissociation constant (KD) of 10-6 M or lower, wherein the antibody competes for binding to PRLR by more than 75% with: 
Antitijelo koje se specifično veže za PRLR sa ravnotežnom konstantnom disocijacije od 106 M ili nižom i koje sadrži 6 hipervarijabilnih regija (CDR), naznačenih time, što:
where R1, R3-R13 are as defined herein and R′ is a protection group such as a carbamate (such as methyl-, ethyl-, tert-butyl-, allyl-, or benzyl-carbamate); whereupon the compound of formula ID is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. 
Kn o gdje su R!, R*-R'* kako je to ovdje definirano a R' je protekcijska grupa kao karbamati (npr. metil-, etil-, tert-butil, alil-, ili benzil-karbamat); nakon čega se spoj formule ID izolira kao slobodna baza ili njezina sol kao farmaceutski prihvatljiva kisela dodatna njezina sol.
The formulation of paragraph 26, wherein the binding agent is: or 
Formulacija prema zahtjevu 22, naznačena time da je sredstvo za vezanje: o f
and in that said microprocessor means (11) are configured to act on the control valves and are programmed for: actuating said control valves independently of one another, varying, according to a predetermined modulation rule, the frequency and the duration of the air jets delivered from each nozzle (2) and the delay time of each nozzle with respect to the successive one in the nozzle actuation sequence, 
- < pokretanje spomenutih kontrolnih ventila nezavisno jedan od drugoga, - variranje, ovisno o prethodno postavljenom modulacijskom pravilu, frekvencije i trajanja mlazova zraka ispuštenih iz svake mlaznice (2) 1 vrijeme odgode svake mlaznice s obzirom na sljedeću u sekvenci pokretanja mlaznica, gdje su spomenute mlaznice (2) montirane na stranicama spomenutog spremnika (1).
before placing the construction material, adding a rheology-modifying agent to the construction material so that the placed material has an increased yield stress when compared to the material during the conveying step. Method according to claim 1, characterized in that the step of placing the construction material comprises extruding the construction material in a pasty form through a nozzle of the deposition head. Method according to claim 1 or 2, characterized in that, after the placement of a first layer of construction material, at least one subsequent layer of construction material is placed onto the first layer, wherein the amount of rheology-modifying agent added to the construction material is selected so as to increase the yield stress so that the first layer does not collapse under the load of said at least one subsequent layer. 
transportiranje tekućeg građevinskog materijala do glave (10) za polaganje, polaganje građevinskog materijala kroz izlazni otvor na glavi (10) za polaganje, kako bi se oblikovao sloj građevinskog materijala, dodavanje sredstva za reološku modifikaciju u građevinski materijal, prije polaganja građevinskog materijala, tako da položeni materijal ima povećanu elastičnu čvrstoću prije nego dođe do stvrdnjavanja, u usporedbi s materijalom za vrijeme koraka transportiranja, pri čemu korak polaganja građevinskog materijala obuhvaća ekstrudiranje građevinskog materijala u obliku paste kroz mlaznicu glave za polaganje (10), te time, da se nakon polaganja prvog sloja građevinskog materijala, polaže najmanje jedan naknadni sloj građevinskog materijala na prvi sloj, gdje je količina sredstva za reološku modifikaciju, koja se dodaje u građevinski materijal, odabrana tako da povećava elastičnu čvrstoću, kako se prvi sloj ne bi urušio pod opterećenjem navedenog najmanje jednog naknadnog sloja.
The compounds of the present invention, in addition to their GnRH receptor antagonist activity, possess a reduced interaction with the major metabolic enzymes in the liver, namely the Cytochrome P450 enzymes. 
Spojevi prema ovom izumu, uz svoju antagonističku aktivnost na receptoru GnRH, također manje ometaju s glavne metaboličke enzime u jetri, primjerice enzime citokrome P4so.
The coating material as recited in claim 1, wherein the aqueous polymer dispersion comprises the copolymer of the fluorinated ethylene and the vinyl ether. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, đa polimerna disperzija sadrži kopolimere fluoriranog etilena i vinil-etera.
A cryogenic tank arrangement according to claim 6, wherein the branch conduits are arranged outside the tank and arranged to gradually approaching the face of the tank when running from the branch point to the connection point. 
Kriogeni spremnik prema zahtjevu 4, naznačen time da su vodovi grananja (32',32") smješteni izvan spremnika i postavljeni da se postupno približavaju prednjoj strani spremnika kada se protežu od točke grananja (30) do spojne točke (24',24").
a compound of formula B-1 chlorothalonil; epoxiconazole and prothioconazole. A method of protecting natural substances of plant or animal origin, which have been taken from the natural life cycle, or their processed forms, which comprises applying to the natural substances of plant or animal origin or their processed forms a combination of components A) and B) in a synergistically effective amount, 
Postupak za zaštitu prirodnih tvari biljnog i/ili životinjskog porijekla koje su preuzete iz prirodnog životnog ciklusa ifili njihovih obrađenih oblika, od napada gljivica, naznačen time, da sadrži primjenu na navedene prirodne tvari biljnog i/ili životinjskog porijekla ili na njihove obrađene oblike, kombinacije komponenti A) i B) prema zahtjevu 1 u sinergistički učinkovitoj količini.
A subsequent polymerase chain reaction (PCR) was performed using the cDNA as template and the oligonucleotides TTTACGCGTGGCCATGCCCATCATGGGCTCCTC and TTTCTAGAATCAGGACACTCCTGCTCCATC as primers for the amplification. 
Posljedično, događa se lančana reakcija polimeraze (PCR) korištenjem cDNA kao predloška i oligonukleotida TTTACGCGTGGCCATGCCCATCATGGGCTCCTC i TTTCTAGAATCAGGACACTCCTGCTCCACT kao primera za amplifikaciju.
Nalmefene for use according to any of claims 1-7, wherein said nalmefene is used in the form of a pharmaceutically acceptable acid addition salt. 
Nalmefen za uporabu prema bilo kojem od zahtjeva 1-8, gdje se nalmefen primjenjuje u obliku farmaceutski prikladne kisele adicijske soli.
Unless the context requires otherwise, a reference in this application to Isomer D includes within its scope not only the free base of the dihydrotetrabenazine but also its salts, and in particular acid addition salts. 
Ukoliko kontekst ne zahtjeva drugačije, reference u ovoj prijavi koje se odnose na Izomer A uključuju unutar dosega prijave ne samo slobodne baze dihidrotetrabenazina već također i njegove soli, te posebno kiselinske adicijske soli.
a plurality of active agent particles comprising crystalline glycopyrrolate, including any pharmaceutically acceptable salts, esters, or solvates thereof, wherein at least 90% of the active agent particle material by volume exhibits an optical diameter of 7 µm or less, said active agent particles are included in the suspension medium at a concentration sufficient to provide a delivered dose of glycopyrrolate of up 20 µg per actuation of the metered dose inhaler; and 
prvu vrstu čestica aktivnog sredstva koje sadrže glikopirolat, uključujući sve njegove farmaceutski prihvatljive soli, estere ili solvate, suspendirane u suspenzijskom mediju u koncentraciji dovoljnoj da se osigura isporučena doza glikopirolata od sve do 15 µg to 80 µg po aktiviranju inhalatora s odmjerenom dozom;
A genetically modified murine animal comprising a humanized IL-6Ra gene comprising a replacement of a murine ectodomain-encoding sequence with a human ectodomain sequence, wherein the humanized IL-6Ra gene comprises murine transmembrane and intracellular domain sequences, wherein the murine animal further comprises a gene encoding a human IL-6, and wherein the genes encoding human IL-6 and humanized IL-6Ra are under control of endogenous murine regulatory elements. 
Genetički modificirani miš koji sadrži humanizirani IL-6Ra gen koji sadrži zamjenu mišje sekvence koja kodira ektodomenu sa ljudskom sekvencom ektodomene, naznačen time da humanizirani IL-6Ra gen sadrži sekvence mišje transmembranske i unutarstanične domene, pri čemu miš dodatno sadrži gen koji kodira ljudski IL-6 i pri čemu su geni koji kodiraju ljudski IL-6 i humanizirani IL-6Ra pod kontrolom regulacijskih elemenata endogenog miša.